Provided by Tiger Trade Technology Pte. Ltd.

Greenwich Lifesciences Inc

16.67
+1.368.88%
Post-market: 16.63-0.0420-0.25%19:56 EDT
Volume:176.79K
Turnover:2.96M
Market Cap:244.69M
PE:-10.56
High:17.48
Open:16.16
Low:15.54
Close:15.31
52wk High:34.10
52wk Low:7.78
Shares:14.68M
Float Shares:7.65M
Volume Ratio:1.46
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5783
EPS(LYR):-1.4302
ROE:-986.32%
ROA:-235.98%
PB:78.50
PE(LYR):-11.66

Loading ...

Greenwich Lifesciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Greenwich Lifesciences Inc Expected to Post a Loss of 33 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Greenwich LifeSciences extends lock-up of directors and officers to 2027

TIPRANKS
·
Aug 10

Greenwich Lifesciences - Extends Lock-up of Directors, Officers, Pre-IPO Investors' Shares to January 31, 2027

THOMSON REUTERS
·
Aug 10

Greenwich LifeSciences Extends Insider Lock-up to Jan. 31, 2027

Reuters
·
Aug 10

Top Executive Doubles Down on Greenwich LifeSciences With Fresh Insider Buy

TIPRANKS
·
Jul 31

Top Executive Makes Bold Insider Move on Biotech Stock

TIPRANKS
·
Jul 30

Greenwich Lifesciences CEO and CFO Snehal Patel Acquires $20,430 of Common Shares

Reuters
·
Jul 29

Top Executive Makes Bold Insider Move at Greenwich LifeSciences

TIPRANKS
·
Jul 28

Greenwich LifeSciences CEO, CFO Snehal Patel Acquires Common Shares Worth $47,005

Reuters
·
Jul 27

Greenwich Lifesciences Announces Approval to Expand Flamingo-01 into the United Kingdom

THOMSON REUTERS
·
Jul 22

Greenwich Lifesciences Wins UK Regulatory Clearance to Expand Flamingo-01 Trial

Reuters
·
Jul 22

Greenwich Lifesciences is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 22

Greenwich Lifesciences, Inc. : H.c. Wainwright Raises Target Price to $69 from $50

THOMSON REUTERS
·
Jul 22

Greenwich Lifesciences Rises as Regulators Allow Expansion of Late-stage Breast Cancer Study

Reuters
·
Jul 20

Greenwich LifeSciences provides clinical and financial updates on Flamingo-01

TIPRANKS
·
Jul 20

Greenwich Lifesciences - Flamingo-01 Phase 3 Objectives Met Following FDA and Ema Review

THOMSON REUTERS
·
Jul 20

Greenwich Lifesciences Provides Clinical Updates on Flamingo-01

THOMSON REUTERS
·
Jul 20

Greenwich Lifesciences - Q2 2026 Burn Rate Expected at $2 Mln; Cash Balance $8.90 Mln as of June 30, 2026

THOMSON REUTERS
·
Jul 20

Greenwich Lifesciences - Flamingo-01 Steering Committee Endorses Study Size Increase and Accelerated Enrollment

THOMSON REUTERS
·
Jul 20